BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News » Press Releases » Page 40

Landmark Stem Cell Clinical Trial Testing Escalating Doses of AST-OPC1 (Oligodendrocyte Progenitors)

By

Below is a press release from Santa Clara Valley Medical Center (SCVMC), a site in the AST-OPC1 SCiSTAR Phase 1/2a clinical trial in complete cervical spinal cord injury, which is being sponsored by BioTime, Inc. (NYSE MKT: BTX) subsidiary Asterias Biotherapeutics (NYSE MKT: AST).

The clinical trial will test the safety of three varying doses of AST-OPC1, which are oligodendrocyte progenitors that have the capacity to differentiate into a variety of brain cells. The California Institute of Regenerative Medicine (CIRM) also released a blog post about the procedure conducted at SCVMC.

The SCiSTAR study being run by Asterias Biotherapeutics is funded in part by a $14.3 million grant from CIRM. [Read more…]

CDI and National Eye Institute to Collaborate on iPSC-Derived Cell Therapies for Retinal Degenerative Disease

By

Headquartered in Madison, Wisconsin, Cellular Dynamics International (CDI) is powerhouse within the induced pluripotent stem cell (iPSC) industry. The company was founded in 2004 and listed on NASDAQ stock exchange in July 2013.  Today, the company has more than than 150 employees, as well as an extremely robust patent portfolio of more than 800 stem cell related patents of which approximately 130 pertain to iPSCs.

In major news released this week, CDI announced that it has partnered with the National Eye Institute to develop cell transplantation therapies for retinal degenerative disease. [Read more…]

Axol Bioscience to Launch Novel iPSC-Derived Cells at ISSCR 2016

By

The human cell culture specialists showcase innovative tools and applications for disease modelling and drug discovery

Cambridge, UK, 1 June 2016: Axol Bioscience, a biotechnology company specialising in the supply of human induced pluripotent stem cell (iPSC)-derived cells has expanded its range of drug discovery and disease modelling tools. Axol will launch three exciting products at International Society for Stem Cell Research (ISSCR) 2016 taking place in San Francisco, CA from 22 – 25 June. This includes: Human iPSC-Derived Atrial Cardiomyocytes, Human iPSC-Derived Endothelial Colony Forming Cells (ECFCs) and axolGEMs (Genetically Edited Models), Axol’s new range of isogenic human iPSC-derived cells carrying disease-relevant mutations developed in partnership with Horizon Discovery plc. Axol and its collaborators will also be presenting an Innovation Showcase and posters highlighting the characteristics and functional applications of its human iPSC-derived neural cells and cardiomyocytes. [Read more…]

Next Biosciences and Genesis Genetics Combine to Consolidate Stem Cell Banking and Genetic Testing within Africa

By

Based in South Africa, Next Biosciences is a unique company.  It owns Netcells, Africa’s largest private stem cell bank. It also recently merged with a local laboratory, Genesis Genetics, making Next Biosciences the only facility on the African continent to offer genetic and metabolic screening, as well as storage of umbilical cord blood and tissue for use in regenerative medicine applications.

As such, Next Biosciences plays a leading role within the South African cord blood banking marketplace and operates within genetic and metabolic screening markets.

To learn more about Next Biosciences and its recent merger with Genesis Genetics South Africa, read the company press release below, printed with permission from the company’s Public Relations advisor, Gina de Villiers. 

Next Biosciences and Genesis Genetics South Africa Combine their DNA

Merger of local leaders in stem cell banking and genetic testing consolidate their position
in African biotechnology industry

Johannesburg, 17 May 2016 — Next Biosciences, a South African leader in stem cell banking, and Genesis Genetics South Africa, the local provider of internationally pioneered genetic technology, have merged to consolidate their position in South Africa’s burgeoning biotechnology industry. As a result, Genesis Genetics South Africa becomes a Next Biosciences company.

The new Next Biosciences group of companies owns Netcells, Africa’s largest private stem cell bank. This is now the only such facility on the continent to offer genetic and metabolic screening as well as storage of umbilical cord blood and tissue for use in various regenerative medical therapies. [Read more…]

Lonza Reports Strong First Quarter in History in Terms of Sales and Earnings

By

The possibilities arising from stem cells have resulted in great commercial interest, with potential applications ranging from their use in the reversal of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, toxicology assessment, and more. To facilitate research resulting from interest in these potential far-ranging applications, a large and growing stem cells research products market has emerged.

One of several large companies selling stem cell research products is Lonza Group. Others competitors include Thermo Fisher Scientific, BD Biosciences, Merck KGaA, Miltenyi Biotec, STEMCELL Technologies, Clontech (a Takara Bio Company), GE Healthcare Life Sciences, and more.

In major news released today, Lonza Group from Basel, Switzerland, reported a record 1st quarter of 2016, recording its “strongest first quarter in history in terms of sales and earnings.”

Lonza has several different business divisions, including Pharma&Biotech, Specialty Ingredients, Custom Manufacturing, and more. One of these divisions is Lonza Bioscience (LBS), which develops and manufactures tools for life sciences researchers. In this April 26, 2016, press release, Lonza states: “Our healthy Bioscience Solutions business showed further improvement compared with the previous year, driven by product introductions and sound demand in all sub-segments.”

To learn more about Lonza’s role within the research products market, view “Stem Cell Research Products – Opportunities, Tools, and Technologies.

To learn more about Lonza’s record first quarter results, read the full press release issued by Lonza Group (below). [Read more…]

BioInformant's World-Class Clients